Bayer acquires rights in Puhe BioPharma cancer drug candidate
By Thomson ReutersMar 26, 2025 | 2:55 AM
FRANKFURT (Reuters) -Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China’s Puhe BioPharma.
Bayer, which did not disclose financial terms, said it had enrolled the first patient to test the drug, a PRMT5 inhibitor that selectively targets MTAP-deleted tumors, in the first phase of clinical trials.
(Reporting by Ludwig Burger, editing by Rachel More)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
